Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01VEJ
|
|||
| Drug Name |
Elapegademase
|
|||
| Synonyms |
Elapegademase [INN]; UNII-9R3D3Y0UHS; Elapegademase [USAN:INN]; 9R3D3Y0UHS
Click to Show/Hide
|
|||
| Indication | Adenosine deaminase defciency [ICD-11: 4A01.1] | Approved | [1] | |
| Immunodeficiency [ICD-11: 4A00-4A85; ICD-9: 279.3] | Phase 3 | [2] | ||
| Company |
Leadiant Biosciences
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adenosine deaminase (ADA) | Target Info | Modulator | [1] |
| BioCyc | Purine nucleotides degradation | |||
| Purine deoxyribonucleosides degradation | ||||
| Purine ribonucleosides degradation to ribose-1-phosphate | ||||
| Adenosine nucleotides degradation | ||||
| Superpathway of purine nucleotide salvage | ||||
| Adenine and adenosine salvage III | ||||
| KEGG Pathway | Purine metabolism | |||
| Metabolic pathways | ||||
| Primary immunodeficiency | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| IL2 Signaling Pathway | ||||
| Panther Pathway | Adenine and hypoxanthine salvage pathway | |||
| Pathwhiz Pathway | Purine Metabolism | |||
| Pathway Interaction Database | p73 transcription factor network | |||
| C-MYB transcription factor network | ||||
| Validated transcriptional targets of deltaNp63 isoforms | ||||
| Validated transcriptional targets of TAp63 isoforms | ||||
| Reactome | Purine salvage | |||
| WikiPathways | Metabolism of nucleotides | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. | |||
| REF 2 | ClinicalTrials.gov (NCT01420627) EZN-2279 in Patients With ADA-SCID. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.